Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate the efficacy and safety of voclosporin administered orally twice daily for the prevention of acute allograft rejection in recipients of a kidney transplant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of ISA247 (Voclosporin) in De Novo Renal Transplantation

NCT00270634

Kidney Diseases

COMPLETED PHASE2

Special Access for the Use of Voclosporin for Kidney Transplantation

NCT01236287

Immunosuppression Transplantation, Kidney

NO_LONGER_AVAILABLE

Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients

NCT04701528

Covid19 Kidney Transplant Infection

COMPLETED PHASE2

Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients

NCT01064791

Renal Transplantation

COMPLETED PHASE2

Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

NCT00895583

Graft Rejection Kidney Transplant Renal Allograft Recipients +1 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a phase III, randomized, multicentre, open-label, concentration-controlled study in subjects undergoing a first or second renal transplant, with induction immunosuppression with an IL-2 receptor antibody (basiliximab), mycophenolate mofetil and steroids.

The primary endpoint to assess non-inferiority will be efficacy failure at the end of Month 12 after randomization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Voclosporin

Group Type EXPERIMENTAL

voclosporin

Intervention Type DRUG

Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled

Tacrolimus

Group Type ACTIVE_COMPARATOR

tacrolimus

Intervention Type DRUG

tacrolimus as per labeled dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

voclosporin

Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled

Intervention Type DRUG

tacrolimus

tacrolimus as per labeled dose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

voclosporin, ISA247

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females aged 18-65 years inclusive at the time of screening.
* Recipients of a first or second deceased donor or living donor renal transplant.

Exclusion Criteria

* Subjects presently receiving immunosuppression for a previously failed transplant.
* Females who are pregnant or nursing or planning to become pregnant during the course of the study, or 3 months after last dose of study medication.
* Sexually-active women of child-bearing potential (including those who are \< 1 year postmenopausal) and sexually-active men who are not practicing a highly effective method of birth control.
* Subjects receiving a HLA identical living related transplant.
* Subjects wth a positive T-cell lymphocytotoxic cross match, or positive flow T and B cell cross match.
* Subjects undergoing primary transplant with a current PRA (or CPRA) ≥ 25%.
* Subjects who experienced graft loss within 1 year of transplant.
* Subjects receiving a kidney from a ABO incompatible donor.
* Subjects receiving a kidney from a deceased donor positive for HIV, HBV, HCV or tuberculosis.
* Subjects receiving a a kidney from a non-heart beating donor.
* Subjects receiving paired (en bloc or paired) kidney transplants.
* Transplantation of multiple grafts (e.g. kidney and pancreas).
* Subjects receiving a kidney with a cold ischemia time \> 30 hours.
* Subjects receiving any transplanted organ other than a kidney.
* Recipients of a bone marrow or stem cell transplant.
* Any systemic infections requiring continued therapy at the time of entry into this study. (Prophylaxis against CMV and/or PCP infection will be permitted).
* Subjects with positive results of the following serological tests: HIV I Ab, hepatitis B virus (HBV) surface antigen (HBsAg), anti-hepatitis B core antibody (HBcAb), and the anti-hepatitis C virus antibody (HCV Ab). Negative results for these serological tests must be documented within 12 months prior to randomization.
* Subjects with active tuberculosis (Tb) requiring treatment within the last 3 years. Subjects with a known positive purified protein derivative (PPD) test are not eligible unless they have completed treatment for latent Tb and have a negative chest X-ray at time of enrollment. PPD testing must have been done within the last 12 months, and a positive result is defined as ≥ 10 mm induration, a Heaf score of \>1 in non-Bacille Calmette-Guérin (BCG) immunized subjects, or \>2 in BCG immunized subjects.
* Subjects with a current malignancy or history of malignancy within 5 years or a history of lymphoma at any time. Subjects can be enrolled with a history of squamous or basal cell carcinoma that has been surgically excised or removed with curettage and electrodessication.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No